Review



alzpath single molecule array simoa p tau217 v2 assay kit  (Quanterix)


Bioz Verified Symbol Quanterix is a verified supplier
Bioz Manufacturer Symbol Quanterix manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    Quanterix alzpath single molecule array simoa p tau217 v2 assay kit
    Patients with AD carrying the TREM2 H157Y variant exhibit more severe disease‐related endophenotypes. (A) Adjusted MoCA scores of TREM2 H157Y variant carriers (GA) and non‐carriers (GG) who are CN or diagnosed with MCI or AD from Study Cohort_1. Data are presented as box‐and‐whisker plots; whiskers indicate minimum and maximum values. Statistical analysis was performed using two‐sample t‐ test. * p < 0.05, ** p < 0.01, *** p < 0.001. (B–D) Normalized volumes of (B) total gray matter, (C) cortex, and (D) subcortical gray matter of TREM2 H157Y variant carriers diagnosed with MCI and AD in Study Cohort_1. Data are presented as the normalized mean, with lower‐ and upper‐class limits retrieved from statistical analysis (Supplementary Method S4). *Adjusted p < 0.05, **adjusted p < 0.01, ***adjusted p < 0.001. (E, F) Plasma levels of <t>(E)</t> <t>pTau217</t> and (F) NfL in TREM2 H157Y variant carriers and non‐carriers who are CN or diagnosed with MCI, or AD from Study Cohort_1. Data are presented as box‐and‐whisker plots; whiskers indicate minimum and maximum values. Statistical analysis was performed using two‐sample t‐ test. * p < 0.05, ** p < 0.01, *** p < 0.001. One value of plasma pTau217 in non‐carriers with AD is missing due to limited plasma volume. (G) Dot plot showing the association between plasma NfL level and age among TREM2 H157Y variant carriers and non‐carriers from Study Cohort_1. Simple linear regression analysis results are presented as regression lines. GG, slope (±standard error) = 0.863 (±0.122); GA, slope (±standard error) = 1.70 (±0.230). AD, Alzheimer's disease; CN, cognitively normal; MCI, mild cognitive impairment; MoCA, Adjusted Montreal Cognitive Assessment; NfL, neurofilament light polypeptide; TREM2 , triggering receptor expressed on myeloid cells 2.
    Alzpath Single Molecule Array Simoa P Tau217 V2 Assay Kit, supplied by Quanterix, used in various techniques. Bioz Stars score: 97/100, based on 223 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alzpath+single+molecule+array/ALZpath+p-Tau+217+v2/pmc12441928-83-9-28
    Average 97 stars, based on 223 article reviews
    alzpath single molecule array simoa p tau217 v2 assay kit - by Bioz Stars, 2026-11
    97/100 stars

    Images

    1) Product Images from "The TREM2 H157Y variant is associated with more severe neurodegeneration in Alzheimer's disease and altered immune‐related processes"

    Article Title: The TREM2 H157Y variant is associated with more severe neurodegeneration in Alzheimer's disease and altered immune‐related processes

    Journal: Alzheimer's & Dementia

    doi: 10.1002/alz.70586

    Patients with AD carrying the TREM2 H157Y variant exhibit more severe disease‐related endophenotypes. (A) Adjusted MoCA scores of TREM2 H157Y variant carriers (GA) and non‐carriers (GG) who are CN or diagnosed with MCI or AD from Study Cohort_1. Data are presented as box‐and‐whisker plots; whiskers indicate minimum and maximum values. Statistical analysis was performed using two‐sample t‐ test. * p < 0.05, ** p < 0.01, *** p < 0.001. (B–D) Normalized volumes of (B) total gray matter, (C) cortex, and (D) subcortical gray matter of TREM2 H157Y variant carriers diagnosed with MCI and AD in Study Cohort_1. Data are presented as the normalized mean, with lower‐ and upper‐class limits retrieved from statistical analysis (Supplementary Method S4). *Adjusted p < 0.05, **adjusted p < 0.01, ***adjusted p < 0.001. (E, F) Plasma levels of (E) pTau217 and (F) NfL in TREM2 H157Y variant carriers and non‐carriers who are CN or diagnosed with MCI, or AD from Study Cohort_1. Data are presented as box‐and‐whisker plots; whiskers indicate minimum and maximum values. Statistical analysis was performed using two‐sample t‐ test. * p < 0.05, ** p < 0.01, *** p < 0.001. One value of plasma pTau217 in non‐carriers with AD is missing due to limited plasma volume. (G) Dot plot showing the association between plasma NfL level and age among TREM2 H157Y variant carriers and non‐carriers from Study Cohort_1. Simple linear regression analysis results are presented as regression lines. GG, slope (±standard error) = 0.863 (±0.122); GA, slope (±standard error) = 1.70 (±0.230). AD, Alzheimer's disease; CN, cognitively normal; MCI, mild cognitive impairment; MoCA, Adjusted Montreal Cognitive Assessment; NfL, neurofilament light polypeptide; TREM2 , triggering receptor expressed on myeloid cells 2.
    Figure Legend Snippet: Patients with AD carrying the TREM2 H157Y variant exhibit more severe disease‐related endophenotypes. (A) Adjusted MoCA scores of TREM2 H157Y variant carriers (GA) and non‐carriers (GG) who are CN or diagnosed with MCI or AD from Study Cohort_1. Data are presented as box‐and‐whisker plots; whiskers indicate minimum and maximum values. Statistical analysis was performed using two‐sample t‐ test. * p < 0.05, ** p < 0.01, *** p < 0.001. (B–D) Normalized volumes of (B) total gray matter, (C) cortex, and (D) subcortical gray matter of TREM2 H157Y variant carriers diagnosed with MCI and AD in Study Cohort_1. Data are presented as the normalized mean, with lower‐ and upper‐class limits retrieved from statistical analysis (Supplementary Method S4). *Adjusted p < 0.05, **adjusted p < 0.01, ***adjusted p < 0.001. (E, F) Plasma levels of (E) pTau217 and (F) NfL in TREM2 H157Y variant carriers and non‐carriers who are CN or diagnosed with MCI, or AD from Study Cohort_1. Data are presented as box‐and‐whisker plots; whiskers indicate minimum and maximum values. Statistical analysis was performed using two‐sample t‐ test. * p < 0.05, ** p < 0.01, *** p < 0.001. One value of plasma pTau217 in non‐carriers with AD is missing due to limited plasma volume. (G) Dot plot showing the association between plasma NfL level and age among TREM2 H157Y variant carriers and non‐carriers from Study Cohort_1. Simple linear regression analysis results are presented as regression lines. GG, slope (±standard error) = 0.863 (±0.122); GA, slope (±standard error) = 1.70 (±0.230). AD, Alzheimer's disease; CN, cognitively normal; MCI, mild cognitive impairment; MoCA, Adjusted Montreal Cognitive Assessment; NfL, neurofilament light polypeptide; TREM2 , triggering receptor expressed on myeloid cells 2.

    Techniques Used: Variant Assay, Whisker Assay, Clinical Proteomics

    TREM2 H157Y variant carriers exhibit dysregulation of blood proteins associated with neurodegeneration and inflammation. (A) Volcano plot showing the association of blood proteins in the NULISAseq CNS Disease panel with the TREM2 H157Y variant among patients with AD from Study Cohort_2. Blue and red dots indicate blood proteins that are significantly ( p < 0.05) downregulated and upregulated, respectively.(B–E) Plasma levels of (B) NfL, (C) NfH, (D) pTau231, and (E) pTau217 of TREM2 H157Y variant carriers and non‐carriers who are CN or diagnosed with AD from Study Cohort_2. Data are presented as box‐and‐whisker plots; whiskers indicate minimum and maximum values. Statistical analysis was performed using linear regression. * p < 0.05, ** p < 0.01, *** p < 0.001. (F) Volcano plot showing the association of blood proteins in the NULISAseq CNS Disease panel with the TREM2 H157Y variant among CN individuals from Study Cohort_2. Blue and red dots indicate blood proteins that are significantly ( p < 0.05) downregulated and upregulated, respectively. AD, Alzheimer's disease; CN, cognitively normal; NfH, neurofilament heavy polypeptide; NfL, neurofilament light polypeptide; TREM2 , triggering receptor expressed on myeloid cells 2.
    Figure Legend Snippet: TREM2 H157Y variant carriers exhibit dysregulation of blood proteins associated with neurodegeneration and inflammation. (A) Volcano plot showing the association of blood proteins in the NULISAseq CNS Disease panel with the TREM2 H157Y variant among patients with AD from Study Cohort_2. Blue and red dots indicate blood proteins that are significantly ( p < 0.05) downregulated and upregulated, respectively.(B–E) Plasma levels of (B) NfL, (C) NfH, (D) pTau231, and (E) pTau217 of TREM2 H157Y variant carriers and non‐carriers who are CN or diagnosed with AD from Study Cohort_2. Data are presented as box‐and‐whisker plots; whiskers indicate minimum and maximum values. Statistical analysis was performed using linear regression. * p < 0.05, ** p < 0.01, *** p < 0.001. (F) Volcano plot showing the association of blood proteins in the NULISAseq CNS Disease panel with the TREM2 H157Y variant among CN individuals from Study Cohort_2. Blue and red dots indicate blood proteins that are significantly ( p < 0.05) downregulated and upregulated, respectively. AD, Alzheimer's disease; CN, cognitively normal; NfH, neurofilament heavy polypeptide; NfL, neurofilament light polypeptide; TREM2 , triggering receptor expressed on myeloid cells 2.

    Techniques Used: Variant Assay, Clinical Proteomics, Whisker Assay

    Related Articles

    Clinical Proteomics:

    Article Title: Blood-based biomarkers of Alzheimer’s disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms
    Article Snippet: Billerica, MA, USA) at the Department of Psychiatry and Neurochemistry, University of Gothenburg. Plasma NfL, GFAP, Aβ42 and Aβ40 were quantified using the commercial Neurology 4-plex E kit (#103670; Quanterix) while plasma p-tau217 was analyzed using ALZpath commercial kit (#104371, Quanterix). Plasma concentrations of p-tau217, NfL, GFAP, Aβ42 and Aβ40 were below the detection limit of the assay

    Biomarker Discovery:

    Article Title: Blood-based biomarkers of Alzheimer’s disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms
    Article Snippet: Billerica, MA, USA) at the Department of Psychiatry and Neurochemistry, University of Gothenburg. Plasma NfL, GFAP, Aβ42 and Aβ40 were quantified using the commercial Neurology 4-plex E kit (#103670; Quanterix) while plasma p-tau217 was analyzed using ALZpath commercial kit (#104371, Quanterix). Plasma concentrations of p-tau217, NfL, GFAP, Aβ42 and Aβ40 were below the detection limit of the assay

    Structural Proteomics:

    Article Title: Blood-based biomarkers of Alzheimer’s disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms
    Article Snippet: Billerica, MA, USA) at the Department of Psychiatry and Neurochemistry, University of Gothenburg. Plasma NfL, GFAP, Aβ42 and Aβ40 were quantified using the commercial Neurology 4-plex E kit (#103670; Quanterix) while plasma p-tau217 was analyzed using ALZpath commercial kit (#104371, Quanterix). Plasma concentrations of p-tau217, NfL, GFAP, Aβ42 and Aβ40 were below the detection limit of the assay

    Isolation:

    Article Title: Blood-based biomarkers of Alzheimer’s disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms
    Article Snippet: Billerica, MA, USA) at the Department of Psychiatry and Neurochemistry, University of Gothenburg. Plasma NfL, GFAP, Aβ42 and Aβ40 were quantified using the commercial Neurology 4-plex E kit (#103670; Quanterix) while plasma p-tau217 was analyzed using ALZpath commercial kit (#104371, Quanterix). Plasma concentrations of p-tau217, NfL, GFAP, Aβ42 and Aβ40 were below the detection limit of the assay



    Similar Products

    alzpath single molecule array  (Quanterix)
    97
    Quanterix alzpath single molecule array
    Alzpath Single Molecule Array, supplied by Quanterix, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alzpath+single+molecule+array/ALZpath+p-Tau+217+Advantage+PLUS/pm42009653-73-9-18
    Average 97 stars, based on 1 article reviews
    alzpath single molecule array - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier
    alzpath single molecule array simoa p tau217 v2 assay kit  (Quanterix)
    97
    Quanterix alzpath single molecule array simoa p tau217 v2 assay kit
    Patients with AD carrying the TREM2 H157Y variant exhibit more severe disease‐related endophenotypes. (A) Adjusted MoCA scores of TREM2 H157Y variant carriers (GA) and non‐carriers (GG) who are CN or diagnosed with MCI or AD from Study Cohort_1. Data are presented as box‐and‐whisker plots; whiskers indicate minimum and maximum values. Statistical analysis was performed using two‐sample t‐ test. * p < 0.05, ** p < 0.01, *** p < 0.001. (B–D) Normalized volumes of (B) total gray matter, (C) cortex, and (D) subcortical gray matter of TREM2 H157Y variant carriers diagnosed with MCI and AD in Study Cohort_1. Data are presented as the normalized mean, with lower‐ and upper‐class limits retrieved from statistical analysis (Supplementary Method S4). *Adjusted p < 0.05, **adjusted p < 0.01, ***adjusted p < 0.001. (E, F) Plasma levels of <t>(E)</t> <t>pTau217</t> and (F) NfL in TREM2 H157Y variant carriers and non‐carriers who are CN or diagnosed with MCI, or AD from Study Cohort_1. Data are presented as box‐and‐whisker plots; whiskers indicate minimum and maximum values. Statistical analysis was performed using two‐sample t‐ test. * p < 0.05, ** p < 0.01, *** p < 0.001. One value of plasma pTau217 in non‐carriers with AD is missing due to limited plasma volume. (G) Dot plot showing the association between plasma NfL level and age among TREM2 H157Y variant carriers and non‐carriers from Study Cohort_1. Simple linear regression analysis results are presented as regression lines. GG, slope (±standard error) = 0.863 (±0.122); GA, slope (±standard error) = 1.70 (±0.230). AD, Alzheimer's disease; CN, cognitively normal; MCI, mild cognitive impairment; MoCA, Adjusted Montreal Cognitive Assessment; NfL, neurofilament light polypeptide; TREM2 , triggering receptor expressed on myeloid cells 2.
    Alzpath Single Molecule Array Simoa P Tau217 V2 Assay Kit, supplied by Quanterix, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alzpath+single+molecule+array/ALZpath+p-Tau+217+v2/pmc12441928-83-9-28
    Average 97 stars, based on 1 article reviews
    alzpath single molecule array simoa p tau217 v2 assay kit - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    Patients with AD carrying the TREM2 H157Y variant exhibit more severe disease‐related endophenotypes. (A) Adjusted MoCA scores of TREM2 H157Y variant carriers (GA) and non‐carriers (GG) who are CN or diagnosed with MCI or AD from Study Cohort_1. Data are presented as box‐and‐whisker plots; whiskers indicate minimum and maximum values. Statistical analysis was performed using two‐sample t‐ test. * p < 0.05, ** p < 0.01, *** p < 0.001. (B–D) Normalized volumes of (B) total gray matter, (C) cortex, and (D) subcortical gray matter of TREM2 H157Y variant carriers diagnosed with MCI and AD in Study Cohort_1. Data are presented as the normalized mean, with lower‐ and upper‐class limits retrieved from statistical analysis (Supplementary Method S4). *Adjusted p < 0.05, **adjusted p < 0.01, ***adjusted p < 0.001. (E, F) Plasma levels of (E) pTau217 and (F) NfL in TREM2 H157Y variant carriers and non‐carriers who are CN or diagnosed with MCI, or AD from Study Cohort_1. Data are presented as box‐and‐whisker plots; whiskers indicate minimum and maximum values. Statistical analysis was performed using two‐sample t‐ test. * p < 0.05, ** p < 0.01, *** p < 0.001. One value of plasma pTau217 in non‐carriers with AD is missing due to limited plasma volume. (G) Dot plot showing the association between plasma NfL level and age among TREM2 H157Y variant carriers and non‐carriers from Study Cohort_1. Simple linear regression analysis results are presented as regression lines. GG, slope (±standard error) = 0.863 (±0.122); GA, slope (±standard error) = 1.70 (±0.230). AD, Alzheimer's disease; CN, cognitively normal; MCI, mild cognitive impairment; MoCA, Adjusted Montreal Cognitive Assessment; NfL, neurofilament light polypeptide; TREM2 , triggering receptor expressed on myeloid cells 2.

    Journal: Alzheimer's & Dementia

    Article Title: The TREM2 H157Y variant is associated with more severe neurodegeneration in Alzheimer's disease and altered immune‐related processes

    doi: 10.1002/alz.70586

    Figure Lengend Snippet: Patients with AD carrying the TREM2 H157Y variant exhibit more severe disease‐related endophenotypes. (A) Adjusted MoCA scores of TREM2 H157Y variant carriers (GA) and non‐carriers (GG) who are CN or diagnosed with MCI or AD from Study Cohort_1. Data are presented as box‐and‐whisker plots; whiskers indicate minimum and maximum values. Statistical analysis was performed using two‐sample t‐ test. * p < 0.05, ** p < 0.01, *** p < 0.001. (B–D) Normalized volumes of (B) total gray matter, (C) cortex, and (D) subcortical gray matter of TREM2 H157Y variant carriers diagnosed with MCI and AD in Study Cohort_1. Data are presented as the normalized mean, with lower‐ and upper‐class limits retrieved from statistical analysis (Supplementary Method S4). *Adjusted p < 0.05, **adjusted p < 0.01, ***adjusted p < 0.001. (E, F) Plasma levels of (E) pTau217 and (F) NfL in TREM2 H157Y variant carriers and non‐carriers who are CN or diagnosed with MCI, or AD from Study Cohort_1. Data are presented as box‐and‐whisker plots; whiskers indicate minimum and maximum values. Statistical analysis was performed using two‐sample t‐ test. * p < 0.05, ** p < 0.01, *** p < 0.001. One value of plasma pTau217 in non‐carriers with AD is missing due to limited plasma volume. (G) Dot plot showing the association between plasma NfL level and age among TREM2 H157Y variant carriers and non‐carriers from Study Cohort_1. Simple linear regression analysis results are presented as regression lines. GG, slope (±standard error) = 0.863 (±0.122); GA, slope (±standard error) = 1.70 (±0.230). AD, Alzheimer's disease; CN, cognitively normal; MCI, mild cognitive impairment; MoCA, Adjusted Montreal Cognitive Assessment; NfL, neurofilament light polypeptide; TREM2 , triggering receptor expressed on myeloid cells 2.

    Article Snippet: We measured plasma phospho‐tau 217 (pTau217) levels with an ALZpath single molecule array (Simoa) P‐Tau217 V2 Assay Kit (104371) and plasma neurofilament light polypeptide (NfL) levels with a Quanterix Neurology 4‐Plex E Advantage Kit (103670) using 120 μL plasma for each assay.

    Techniques: Variant Assay, Whisker Assay, Clinical Proteomics

    TREM2 H157Y variant carriers exhibit dysregulation of blood proteins associated with neurodegeneration and inflammation. (A) Volcano plot showing the association of blood proteins in the NULISAseq CNS Disease panel with the TREM2 H157Y variant among patients with AD from Study Cohort_2. Blue and red dots indicate blood proteins that are significantly ( p < 0.05) downregulated and upregulated, respectively.(B–E) Plasma levels of (B) NfL, (C) NfH, (D) pTau231, and (E) pTau217 of TREM2 H157Y variant carriers and non‐carriers who are CN or diagnosed with AD from Study Cohort_2. Data are presented as box‐and‐whisker plots; whiskers indicate minimum and maximum values. Statistical analysis was performed using linear regression. * p < 0.05, ** p < 0.01, *** p < 0.001. (F) Volcano plot showing the association of blood proteins in the NULISAseq CNS Disease panel with the TREM2 H157Y variant among CN individuals from Study Cohort_2. Blue and red dots indicate blood proteins that are significantly ( p < 0.05) downregulated and upregulated, respectively. AD, Alzheimer's disease; CN, cognitively normal; NfH, neurofilament heavy polypeptide; NfL, neurofilament light polypeptide; TREM2 , triggering receptor expressed on myeloid cells 2.

    Journal: Alzheimer's & Dementia

    Article Title: The TREM2 H157Y variant is associated with more severe neurodegeneration in Alzheimer's disease and altered immune‐related processes

    doi: 10.1002/alz.70586

    Figure Lengend Snippet: TREM2 H157Y variant carriers exhibit dysregulation of blood proteins associated with neurodegeneration and inflammation. (A) Volcano plot showing the association of blood proteins in the NULISAseq CNS Disease panel with the TREM2 H157Y variant among patients with AD from Study Cohort_2. Blue and red dots indicate blood proteins that are significantly ( p < 0.05) downregulated and upregulated, respectively.(B–E) Plasma levels of (B) NfL, (C) NfH, (D) pTau231, and (E) pTau217 of TREM2 H157Y variant carriers and non‐carriers who are CN or diagnosed with AD from Study Cohort_2. Data are presented as box‐and‐whisker plots; whiskers indicate minimum and maximum values. Statistical analysis was performed using linear regression. * p < 0.05, ** p < 0.01, *** p < 0.001. (F) Volcano plot showing the association of blood proteins in the NULISAseq CNS Disease panel with the TREM2 H157Y variant among CN individuals from Study Cohort_2. Blue and red dots indicate blood proteins that are significantly ( p < 0.05) downregulated and upregulated, respectively. AD, Alzheimer's disease; CN, cognitively normal; NfH, neurofilament heavy polypeptide; NfL, neurofilament light polypeptide; TREM2 , triggering receptor expressed on myeloid cells 2.

    Article Snippet: We measured plasma phospho‐tau 217 (pTau217) levels with an ALZpath single molecule array (Simoa) P‐Tau217 V2 Assay Kit (104371) and plasma neurofilament light polypeptide (NfL) levels with a Quanterix Neurology 4‐Plex E Advantage Kit (103670) using 120 μL plasma for each assay.

    Techniques: Variant Assay, Clinical Proteomics, Whisker Assay